Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | PPARD | Q03181 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.53 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14977098 | 1.00 | CNR1 (0.58) | CNR1L3MBTL1GAAPPARGPPARD | |
| SCHEMBL14977145 | 1.00 | CNR1 (0.58) | CNR1L3MBTL1GAAPPARGPPARD | |
| SCHEMBL14977425 | 1.00 | CNR1 (0.58) | CNR1L3MBTL1GAAPPARGPPARD | |
| SCHEMBL16302951 | 0.91 | L3MBTL1 (0.56) | CNR1L3MBTL1GAAPPARGPPARD | |
| SCHEMBL16265104 | 0.83 | CYP1A1 (0.55) | L3MBTL1GAAPPARGPPARACA1 | |
| SCHEMBL16743655 | 0.83 | PPARA (0.55) | L3MBTL1GAAPPARGPPARDPPARA | |
| SCHEMBL16302949 | 0.82 | PSEN1 (0.49) | CNR1PPARGPPARDPPARAPSEN1 | |
| SCHEMBL16743458 | 0.82 | EPHX1 (0.63) | PPARGPPARDPPARAHDAC1HDAC2 | |
| SCHEMBL8594554 | 0.82 | EPHX2 (0.63) | CNR1PPARGPPARACNR2 | |
| SCHEMBL18259440 | 0.82 | CNR1 (0.68) | CNR1L3MBTL1GAASOAT2SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070212302-A1 | Preparation and Use of a Stable Formulation of Allosteric Effector Compounds | ALLOS THERAPEUTICS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| EP-1496863-A4 | PREPARATION AND USE OF A STABLE FORMULATION OF ALLOSTERIC EFFECTOR COMPOUNDS | ALLOS THERAPEUTICS INC (US) | 2006-10-04 | — | — | EP | disclosed |
| US-7097825-B2 | Methods and reagents to acquire MRI signals and images | ALLOS THERAPEUTICS, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1381311-A4 | METHODS AND REAGENTS TO ACQUIRE MRI SIGNALS AND IMAGES | ALLOS THERAPEUTICS INC (US) | 2005-04-27 | — | — | EP | disclosed |
| EP-1496863-A2 | PREPARATION AND USE OF A STABLE FORMULATION OF ALLOSTERIC EFFECTOR COMPOUNDS | Allos Therapeutics, Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1468680-A2 | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | Virginia Commonwealth University Intellectual Property Foundation, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1236711-B1 | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | UNIV VIRGINIA COMMONWEALTH (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1381311-A2 | METHODS AND REAGENTS TO ACQUIRE MRI SIGNALS AND IMAGES | Allos Therapeutics, Inc. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030232887-A1 | Preparation and use of a stable formulation of allosteric effector compounds | ALLOS THERAPEUTICS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003086324-A2 | PREPARATION AND USE OF A STABLE FORMULATION OF ALLOSTERIC EFFECTOR COMPOUNDS | ALLOS THERAPEUTICS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-0471811-B1 | ALLOSTERIC HEMOGLOBIN MODIFIERS | INNOVATIVE TECH CENTER (US) | 1995-12-27 | — | — | EP | disclosed |
| US-5432191-A | Ring-substituted phenoxymethyl /or substituted methyl/ carboxylates | THE CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1995-07-11 | — | — | US | disclosed |
| EP-0585366-A4 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD. | CT FOR INNOVATIVE TECHNOLOGY (US) | 1994-03-17 | — | — | EP | disclosed |
| EP-0585366-A1 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1994-03-09 | — | — | EP | disclosed |
| US-5290803-A | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | THE CENTER OF INNOVATIVE TECHNOLOGY (US) | 1994-03-01 | — | — | US | disclosed |
| US-5250701-A | 2-(Phthalomidomethylphenoxyalkanoic acid or ester; wound healing agents; antiischemic agents; blood storage; antidepressants; Alzheimer's disease; schizophrenia | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1993-10-05 | — | — | US | disclosed |
| US-5248785-A | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-09-28 | — | — | US | disclosed |
| WO-1992020335-A1 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1992-11-26 | — | — | WO | disclosed |
| US-5122539-A | Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1992-06-16 | — | — | US | disclosed |
| US-5049695-A | Substituted diphenyl carbamates | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1991-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070212302-A1 | Preparation and Use of a Stable Formulation of Allosteric Effector Compounds | PRKAA2, PDE7A, CHRM3 | CNR1 414/4885L3MBTL1 4288/4885GAA 3769/4885 |
| US-20030232887-A1 | Preparation and use of a stable formulation of allosteric effector compounds | PRKAA2, PDE7A, CHRM5 | CNR1 482/4885L3MBTL1 4419/4885GAA 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.